摘要
免疫炎症反应在慢性阻塞性肺疾病(COPD)中发挥重要作用。诱导性支气管相关淋巴组织(iBALT)与COPD异常免疫炎症反应的关系非常密切。然而,目前COPD中iBALT的产生机制及临床意义尚未完全明确。本文综述了近年来关于iBALT发生机制、标志物及其靶向治疗药物的研究进展,可为COPD免疫炎症反应的预防、治疗提供新的思路。
Immune inflammatory response plays an important role in the chronic obstructive pulmonary disease(COPD).There is a close relationship between the inducible bronchus-associated lymphoid tissue(iBALT)and abnormal immune inflammatory response of COPD. However,at present,the mechanism and clinical significance of iBALT in COPD are not completely clear. This article reviews the research progress on the mechanism,biomarker and targeted therapeutic drug of iBALT in recent years,which can provide new ideas for the prevention and treatment of immune inflammatory reaction of COPD.
作者
蔡星璇
林娇娇
贾俊青(指导)
CAI Xing-Xuan;LIN Jiao-Jiao;JIA Jun-Qing(Fenyang Hospital of Shanxi Medical University,Fenyang 032200,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2021年第16期2042-2046,F0004,共6页
Chinese Journal of Immunology
基金
2019年吕梁市科技计划项目(2019SHZ41)。
关键词
慢性阻塞性肺疾病
诱导性支气管相关淋巴组织
标志物
靶向药物
Chronic obstructive pulmonary disease
Inducible bronchus-associated lymphoid tissue
Biomarker
Targeted drug